RespireRx Pharmaceuticals Inc (CE) (RSPI) News

Happy Easter! ✝️ 🐰 🌸

Happy Sunday to all . GLTA

That is why it is only logical for these assets to be structured with a higher class of investor, more liquidity and support. This could be a premier drug discovery phase company trading on Nasdaq or such.

Those who truly invested long including all the equity-linked positions from company individuals and acquired positions way undervalued (peanuts) than what a better trading exchange would have provided is sitting in a very good place as these assets mature into human clinical studies in the coming months and beyond.

Reading a bit more about NIH HEAL program and I am thinking more and more that most likely there is a partner(s) already identified.

I read where NIH encourages that early in the process to help package all the various information needed for IND. It is one thing to advance into tier 3, IND enabling, but another to also facilitate the details, like manufacturing and clinical support/locations, etc....

Looking at pharma deals, obviously have mentioned a competitor gabakine SAN711 with a nice deal in phase 1, and with KRM-ll-81 likely having a better selectivity profile and addressing both pain and epilepsy could be magnitudes better deal. A lot of speculation on this support forum and from company about how they structure all the assets. Lilly acquired an asset from Scorpion for up to 2.5 billion in milestones and sale targets, etc but Scorpion was noted to also create a new company to spin out all the other non-acquired assets and people and Lilly took a minority position in that newco.

Seeing what they are hinting at with EndeavourRx, LLC I wonder if something similar is in the works here. Strike a deal with BP after KRM-ll-81 has an IND package and ready for phase 1 while then spinning out the rest of the neuromodulator platform to a newco that could be traded on a different exchange. I suppose to they could utilize RSPI entity and with a significant upfront payment and milestones incoming they could find a RM or M&A route to Nasdaq or such down the road.

Your saying this because you have no equity in the stock but trust me when I say when u got 15k in a stock 002 to 0005 makes a huge difference. Penny stocks litteraly evolve around the micro decimal movement lol

These are results for “What is the potential for RespireRX to become a multi billion dollar company?”

AI Overview

RespireRx Pharmaceuticals Inc. has the potential to become a multi-billion dollar company, particularly if it can successfully develop and market drugs for obstructive sleep apnea (OSA) and other sleep disorders. The company's focus on the relatively underserved OSA market, with a large patient population and limited approved treatment options, offers a significant opportunity for growth.
Here's a more detailed look:
Strengths and Potential:
• Untapped Market:
OSA is a prevalent condition affecting millions, with a significant unmet need for effective and convenient treatment options.
• Lack of Approved Drugs:
Unlike some other sleep disorders, there are limited FDA-approved medications specifically targeting OSA.
• R&D Pipeline:
RespireRx has a pipeline of potential drugs, including dronabinol, which has shown promise in preclinical and clinical trials for OSA.
• Strategic Partnerships:
Collaborations with organizations like the US Department of Defense can provide funding and expertise, accelerating research and development.
• Market Valuation:
RespireRx's market valuation has seen significant growth in recent months, reflecting investor confidence in its potential.
Challenges and Considerations:
• Competition:
While the market is underserved, other companies may also be developing treatments for OSA, creating competition.
• Drug Development Risks:
The drug development process is inherently risky, with the possibility of trials failing or regulatory hurdles.
• Market Acceptance:
Even if a drug is approved, it needs to gain acceptance among physicians and patients, which can be influenced by factors like cost and convenience.
• Financing:
Maintaining the company's growth requires ongoing investment and fundraising, which can be challenging in the current market.
Overall:
RespireRx's future trajectory is linked to the success of its drug development pipeline and its ability to navigate the challenges of the pharmaceutical industry. While the market potential is significant, the company needs to demonstrate consistent progress in its clinical trials, regulatory approvals, and market adoption to achieve its multi-billion dollar valuation goals.

Is triple zero really "well below where we are now"?

18 hundredths of a cent/share. Do I have that right? Doesn't sound like much.

It's management that has done the capitulating when it comes to the market for the common. The failure to file, something that they COULD have done, says to me that they have given up.

The fact that this stock would be beyond parabolic is an understatement of course!

Nah it would've tanked the stock to triple zero. Well below where we are now. So considering that we are holding up well

Many of these assets need resources and funding to move forward and while they have potential seem to be in a "prove it" mode before any BP will get interested.

RSPI doesn't have personnel or manufacturing or significant clinical expertise to take KRM-ll-81 further. The baton needs to be handed off, that is clear. The CEO and CFO are venture capitalists so I am sure they understand their position. I would expect someone to license KRM-ll-81 coming out of NIH preclincals. An entire buyout doesn't make sense to me as RSPI can develop these other candidates further. Epilepsy IND enabling, preclinicals new OSA formula, ampakine grant funding for maybe more IND enabling?? These activites can create significant value down the road. Right now, they need to get as much as possible going with KRM-ll-81 which is their prime asset and then parlay that success into funding to further the pipeline. This is what early stage pharmas do and they build support and resources along the way.

Whatever this strategy is.... well this forum has a dozen different ideas...

"That fact by itself would have tanked the share price to where it is now even if the Company wasn't in the Expert Market."

Sounds like you are looking for or wanting capitulation here.

RSPI has SO MANY ASSETS in the pipeline, a BP deal surely is in place, but the itemization of each assets treatment would have Tesla's, the scientist not the company, head spinning?
Dr. Lippe didn't carry these curative and remedying as long as he has to short change their efficacy, which might NEED LENGHTHY EVALUATING DISCUSSION with all concerned in inking a deal?
The creation of an international Pharma company, an offshoot from a BP seeking a deal with RSPI might be the easier way to go, hiring peers of Dr. Lippe to progress the assets forward rather than trying to slot each into  existing cubbies holes within the existing BP?
LIPPA has transparently shared all he could about his collective meritocracy of assets.  I would think staffing g a NEW OFFSHOOT would be creative and not put anyone else or their ego in jeopardy...or at least be the least threatening and most productive avenue going forward,  not in any small measure bypassing this tarriff-fest idiocy plaguing much if not all of  global trade?
The biggest and best in business today and going forward is HOW business models are innovating and inventing and experimentally forged for optimality AND sustainability?

"they put out a very nice shareholder letter several months ago"
That's how you want to characterize this? Very nice?
https://www.marketscreener.com/quote/stock/RESPIRERX-PHARMACEUTICALS-111313448/news/RespireRx-Pharmaceuticals-Inc-CFO-and-CEO-Issue-Letter-to-Stockholders-Stakeholders-Strategic-and-49007610/

"If we have not filed all required reports within fifteen days from the date of the letter(2/3/25), we may be subject, without further notice to an administrative proceeding to revoke our Exchange Act registration and subject to suspension of trading."
That fact by itself would have tanked the share price to where it is now even if the Company wasn't in the Expert Market.

Do you think maybe they already have the deal/NDA all lined up with a BP pending the finalization of the IND enabling studies with HEAL and that is why they went EM... Curious all this after the CEO interview and discussing how remarkable KRM-ll-81 is and opening "purse strings"?

If that was the case, then maybe there is some logic of going the EM route. Which if that logic is true, then any of these shares/scraps floating around are like gold.

They are still required to disclose material events, so it is not like the EM provides them cover to not do so. So is an IND close, phase 1 close, etc?

I am not sure about all that..

This is still trading on the EM, and "expert" investors could still buy this up if they wanted too and really going the EM route facilitated a 2 week selloff of 300+ million in volume right before they went to the EM... Not much logic in that. And who accumulated all those shares with confidence?

What funds are you talking about? The 100k loan from the BOD, which many assumed was to pay for the filings...

Would it be possible that they allowed themselves to go to the EM to block the possibility of a hostile takeover? They definitely did not have the funds available to defend themselves. A BF would've had easy Pickens for buying up the market at even a dollar a share if they have several big items. Then it would be a huge discount to perform the hostile takeover. It would make sense then how they got the funds to move topics slightly forward with the investors agreeing to wait for significant progress before being able to sell their shares. Could that be because the investors were shown the potential and had to sign a NDA themselves? Food for thought.

My guess is they are waiting to ink that large deal, have the market valuation explode and then assess what their options are in terms of trading platforms and what candidates they fund forward or who they partner with. Obviously they want to attact epilepsy with their gabakine program and hopefully grant funding, who knows what they are thinking with OSA or ampakines at this point. Seems to both be in-waiting mode as well as they both need cash to move forward...

No its not. Being on the EM is embarrassing for a PUBLICLY TRADED COMPANY....

LT - Isn't being on EM like being a private company and those of us who managed to invest are the equivalent of venture capitalists? The leverage is having an incredible pipeline ... and lead to the equivalence of an IPO on the NASDAQ? Ahhh,,, but to dream.... is there a pot of gold at the end of our rainbow?

I am not sure how. There is no leverage when your market valuation is peanuts and you have no outlet to raise the smallest amount of capital.

And of course the presentation and look of it all gives a non serious appearance. I think what is more likely is as some others here have alluded to is that a NDA is and has been already in place with a BP. It would make some sense. The NIH wants to accelerate development of opioid mitigation therapies, so transitioning from tier 2 into tier 3 IND enabling smoothly would likely involve some BP input as who is going to take the baton going forward. RSPI has zero capacity and even less on the EM.

Assuming they are nearing exiting IND enabling, they will need partners to go forward. Maybe the NIH would help facilitate this, but I do not beleive the NIH pays for all costs in development in phase 1-2-3 clinicals as BP would be better situated to approach devleopment, deciding on indications, manufacturing, marketing strategies,etc, etc...

Could it be possible a deal has mostly been in place with the caveat of just finishing up all that was needed in tier 3 and IND enabling package, etc??

I am beginning to wonder if being on EM is to RSPI's advantage. By keeping the stock price stable has an advantage in negations with big pharma (an assumption). I also wonder if more than one suitor is interested.

I stand corrected. I guess it does help some who are able to accumulate what few shares are available on the EM.

I guess my point is more along the lines of building investor interest, developing that much needed professional touch to presentation and communication, attracting resources whether people or collaborative, positioning the company/assets to capitalize on success, etc, etc...

GLTU with those shares, that will be a nice ROI if/when they can strike a deal to get KRM-ll-81 into phase 1/2 with a BP similar to the Acadia/Saniona deal last year for their gabakine.

Congrads , I wish as do a few others that we could have bought here in the states . GLTA

Sitting for 9+ months in the EM has benefitted nobody? I managed to acquire 8,000,000 shares for $10,320.

We can only hope so...lol

IMO a better strategy would have been to establish clarity with investors and stakeholders as to the intent of going to the EM and rough out some timeframe as well as what are the benefits in doing so? Mostly fixes the share structure while negotiating deals and funding options? Removes distractions and short term interests? Better focus for IND enabling strategies?

They could have then focused energies on professional presentation of the company and the assets, building potential resources and investor interest while KRM-ll-81 was progressing instead of all these questions and wishy washy everyone is clueless to their intent and really why. Created significant and understandable consternation and anxiety which was completely unnecessary IMO. And heck the valuation could have been more true to their internal estimates which could have opened more doors and certainly added flexibility.

So fingers crossed they can begin to ink those funding deals and BP partnerships and take this stellar science and logical positioning into the clinical for the benefit of all. Sitting for 9+ months in the EM has benefitted nobody.

100% . Method behind the madness here.

Yeah, the CEO and CFO has been involved with venture capital their entire careers it appears. There is a strategy to everything.

I think the story here is rather simple, yet this EM path very unusual and chalking that one up to the dumb OTC playground.

The OSA and ampakine platforms have been hampered by lack of funding for years, well before the gabakine platform entered. The OTC provides little flexibility to move on those assets as liquidity and significant capital is hard to come by. They essentially have been stating this in their filings for a long long time.

The progress with the HEAL program is significant and I think the CEO interview tells the entire story. The NIH confirmed Respire's preclinical results with KRM-ll-81. It then progressed into tier 3 NIH trials, which is stated to be IND enabling studies, prepping for phase 1. CEO sounded geuinely excited about it as well as intent to open investment community "purse strings" and many probably accumulated more shares on this move into tier 3 NIH. The NIH HEAL is for opioid mitigation/pain management therapies. This is high profile. The progress also likely allowed Respire to also pursue IND enabling for epilepsy, the source of the grant application work with the consultants which they had high review scores on and hopefully have a status update soon on if funded...

So anyone who has read their filings, the publications and see all the insider equity linked positions and read about competitor compounds, especially the gabakine deal between Saniona and Acadia can see this might have a good chance of becoming something special and certainly worth leaps and bounds more than the valuation on this EM "market". On top of that they put out a very nice shareholder letter several months ago spelling out significant goals and activities they intend to get going for the entire pipeline. None of this happens until major investment. Which I think all of this is waiting on.

It's on purpose. Lot going on behind the scenes here . Mine are for sale at .10 !

Zero excuse why Jeff hasn't filed the Form 15 to get this off EM. Either complete incompetence, or purposely being done this way. 
Regardless of which one is true, neither is acceptable. 

Some believe they prefer a more sustainable appreciation, gradual flight..

Starting from peanuts, it still will appear to be a rocket ride just getting current and updating status of a dozen or more items that they have not touched on.

Selling or licensing any of their candidates will be the larger booster rides. The largest would be whatever comes out of the NIH HEAL program. IND and initial phase 1 funding from NIH or will BP get involved before any human trials?

I agree. Probably much back n forth before anything would happen and from bigtalan communication not much if anything has come from SEC.

Would be hard for phantom shares to set fair market value as well as warrants and debt holders to convert if they let that lapse as well. We're 1/3 of the way done with 2025 and many months removed from the shareholder letter content as well as institutional conferences and reasonable assumption much further along with preclinical toxicology and grant funding awards, etc...

Time to move forward.

Interesting. Someone had to have it. Probably more of that coming as timelines compress.

Hope so been brewing for long enough time for the lid to burst. Ignite us towards the moon lol 

lol I agree with u but I personally am inclined to believe we are ways away from revocation or complete removal. Paper work should've began to process back in February according to the 8-k update. Now we sit in April on our way to May still no word from sec. If I remember correctly Jeff claimed to have gotten in contact with sec officials. And now friends yet again we have another unknown variable as we are in the dark evolving the communication shared in between them. Perhaps they shared hints of a deal and the SEC in response is holding back the hound dogs. Hopefully the 'optimistic' update before the end of month breaths a new air around us where we feel revived.

Needs a filing. Will be revoked.

Nothing matters right now about how great this company is or isnt.

They need to file. No excuse.

File a simple page Form 15 to save it.

1 second before close, a 1 million shares transaction, just 2300$. Symbolic.

Well, I think we are all watching closely and waiting for a flood of information, funding and clinical progress to unveil itself.

We can't forget they presented at I think at least 2 significant institutional investor conferences going on almost 3 months ago... So between possible institutional, BP and NIH dealings and who knows what else with in-licensing and more grant fundings, there could be quite the stew brewing...

In an odd way, this is kinda like that classic hot rod... The doors and hood could be off it and several mechanics working on it and people would probably pass by not paying much attention, but place a cover on the whole thing and have mechanics work on it, then curiosity and interest increases.. what ya got under there... what you doing under there... when can we see it...

Numerous reports world wide tha BP wants to keep people sick and on rxs that treat symptoms but don't cure.. as one young doctor told me in 2016. "Vote for _____ Tuesday, health care is a business."

Getting old that's for sure.........................

This company really needs to get off its ass and start looking at a company that will promote its products and bring all the new technology to light. It is a travesty that this company has some highly skilled individuals that can do anything in the scientific community, but when it comes to promoting their products and gathering resources such as wealth that will further their research. they seem to be lost they need to get somebody who has the advertising and the promotional skills in their wheelhouse and get them on board with this company, it wouldn't take that much money.

AI Overview of RSPI

In 2023, RespireRx Pharmaceuticals Inc. demonstrated potential for success in its drug development programs, particularly in its focus on neuromodulators and pharmaceutical cannabinoids. Key milestones included the establishment of subsidiaries like ResolutionRx Ltd for its cannabinoid program and the announcement of a new formulation of dronabinol for obstructive sleep apnea. RespireRx also received funding from the Department of Defense for a Phase 2 clinical study on its lead AMPAkine, CX1739, for spinal cord injury.

All things considered....

If the intention of the NIH HEAL program is to accelerate and support development of therapeutics that can address the opioid/pain management arena, then given the tier 3 status beginning well over a year ago and RSPI stated toxicology ongoing awhile ago now it is reasonable that a BP/support structure to take into clinical trials should be well on its way to being established.

And logically, they stated they needs funds to support the phase 2 SCI trial, funds to advance the OSA program, funds to pay the consultant fees for the epilepsy grant they are hopefully going to achieve, funds for admin/SEC filings. All this and still planning to file for MORE grant funding for ampakines which will need support capital. As well as entertaining in-licensing more compounds which is not free... un huh...

Not a poker player, but I think we can reason a good idea what they have in their back pocket to go forward with... Excited to see how they position everything in the coming weeks and months.. GLTA.

Yes, bigtalan, sorry and thanks, meant less than $1,250 😊

My guess is the only current ampakines they will focus on is the CX717 and CX1739….

Maybe the nanoparticles help them revisit older compounds and design newer ampakines? I also believe there might be gabakine selectivity designs to explore in this regards as well.

Science team is stellar in discovery and if they can parlay KRM-ll-81 into funding/BP deals for pain and epilepsy indications…. I can only imagine what else they can do..

As I noted previously CX929 can be orally administered in a recent study with spectacular results reflective of what is discussed here. I can only surmise that RSPI has an even better compound.

September 1, 2006
Ampakines May Reverse Age-Related Memory Loss
Author(s):

Myra Partridge
Ampakines, agents that have been shown to enhance memory, appear to trigger endogenous brain-derived neurotrophic factor (BDNF), a natural mechanism in the brain that could restore neuronal viability and synaptic plasticity through increased trophic support.


A new therapy may reverse age-related cognitive decline, even after the drug has left the body, according to researchers from the University of California, Irvine (UC Irvine). Ampakines, agents that have been shown to enhance memory, appear to trigger endogenous brain-derived neurotrophic factor (BDNF), a natural mechanism in the brain that could restore neuronal viability and synaptic plasticity through increased trophic support.

Because previous studies have demonstrated that hippocampal CA1 basal dendritic field deficits in the stabilization of long-term potentiation (LTP) occur in middle-aged adults, the UC Irvine team, lead by Christine Gall, PhD, professor of anatomy and neurobiology, and Gary Lynch, PhD, professor of neuroscience, focused their study on middle-aged rats. Two groups of rats were treated in vivo twice a day for 8 days; one group received an ampakine, the other received placebo. In the first 4 days, the ampakine-treated rats received injections of saline plus 15% to 20% 2-hydroxypropyl-beta-cyclodextrin. In the next 4 days, they received injections of 5 mg/kg of ampakine CX929, a proprietary compound from Cortex Pharmaceuticals (Irvine, California). When the rats' brains were examined using electrophysiology and protein measures, they showed increased BDNF protein levels in the cortical telencephalon and restored stabilization of basal dendritic LTP.

The results of the study suggest that even brief exposure to ampakines can elevate endogenous BDNF protein levels. Restoration of LTP was found in the rats more than 18 hours after the ampakine had cleared from the animals' bodies. This was significant, according to the authors, because the therapy has a half-life of only 15 minutes. Therefore, they concluded that daily ampakine treatments might have enduring effects.

According to the authors of the study, the results also suggest that neurotrophin levels in the adult brain can be regulated in a way that is minimally disruptive to physiology and behavior. The authors hope that therapies using ampakines may eventually be used to treat age-related memory impairment as well as CNS disorders such as Alzheimer disease and schizophrenia.

The citation for this study is Rex CS, Lauterborn JC, Lin CY, et al. Restoration of long-term potentiation in middle-aged hippocampus after induction of brain-derived neurotrophic factor. J Neurophysiol. 2006;96:677-685.

Is this dollar and a quarter 1.250 or did you mean 1,250

Thanks and no problem BuccaneerGoblin51 (we all make mistakes from time to time) it's all good 😃
Glad your out of the hospital. Take it easy and have a great day.

No. My bad. Misunderstood previous posts. 

Thank you INV4.  I am applying week out of hospital and no insulin yet at my pharmacy and fatigued and well...good prognosis going into the future, but that is just one of many mental mistakes, like the provisional patent app me thought was recent.
My old moniker was DJ56.
somehow when I got back on after  several months they gave me the one above.
I will take another month Or 2 off as under any moniker I hate making such simple mistakes.
Thanks, again, for your and IT'S  keeping the info in posts on the up and up.
Apologies to all for my multiple errors.
Glta